ACAD vs STE
ACADIA Pharmaceuticals Inc. vs Steris — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
62
Buy
VS
| Metric | ACAD | STE |
|---|
| AI Score |
62
|
54
|
| Price |
$29.50
|
$237.96
|
| P/E Ratio |
13.11×
|
29.02×
|
| ROE |
31.9%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
44.4%
|
| Debt / Equity |
0.06×
|
0.28×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
59.6
|
62.9
|
| Beta |
0.845
|
0.914
|
| Expected Upside |
—
|
+6.2%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus STE.
ACAD leads by 8 points.
ACAD scores 62/100 (Buy) versus STE at 54/100 (Watch).
ACAD Committee View
60% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 22.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
STE Committee View
50% agreement
4 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 9 articles, 14d). Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- News sentiment is positive (+0.33 across 9 articles, 14d) — News
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical